pyrroles has been researched along with atogepant in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 25 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tepper, D | 1 |
| Boinpally, R; Bondiskey, P; Colón-González, F; Dockendorf, MF; Kraft, WK; Liu, W; Matthews, CZ; Min, KC; Mixson, L; Panebianco, D; Xu, J | 1 |
| Adams, AM; Brin, MF; Burstein, R; Melo-Carrillo, A; Schain, AJ; Strassman, AM | 1 |
| Boinpally, R; Borbridge, L; Butler, M; Jakate, A; Periclou, A | 1 |
| Boinpally, R; Borbridge, L; Butler, M; McGeeney, D; McNamee, B; Periclou, A; Yao, L | 1 |
| Ailani, J; Finnegan, M; Goadsby, PJ; Guo, H; Lipton, RB; Miceli, R; Severt, L; Trugman, JM | 1 |
| Ailani, J; Dabruzzo, B; Finnegan, M; Guo, H; Lipton, RB; Lu, K; Miceli, R; Schwedt, TJ; Severt, L; Silberstein, SD; Tassorelli, C; Trugman, JM | 1 |
| Deeks, ED | 1 |
| Boinpally, R; Butler, M; Jakate, A; Periclou, A | 1 |
| Dai, Q; Meng, J; Tao, X; Wang, W; Wang, Z; Yan, Z; Zhou, Q | 1 |
| Balasundaram, MK; Singh, A | 1 |
| Avallone, R; Ferrari, A; Rustichelli, C | 1 |
| Adams, A; Brin, MF; Burstein, R; Houle, TT; Melo-Carrillo, A; Strassman, AM | 1 |
| da Silva, MRR; Dos Santos, JBR | 1 |
| Harris, PWR; Hay, DL; Walker, CS | 1 |
| Conway, C; Howell, BA; Siler, SQ; Watkins, PB; Woodhead, JL | 1 |
| Altamura, C; Brunelli, N; Fofi, L; Marcosano, M; Vernieri, F | 1 |
| Blumenfeld, AM; Dabruzzo, B; Dodick, DW; Finnegan, M; Li, Y; Lipton, RB; Lu, K; McAllister, P; Miceli, R; Pozo-Rosich, P; Severt, L; Trugman, JM | 1 |
| Heinz, BA; Huang, X; Johnson, KW; Li, B; Li, X; Yu, J | 1 |
| Ailani, J; Bedrin, K | 1 |
| Abreu, J; Li, D; Tepper, SJ | 1 |
| Ashina, M; Dabruzzo, B; Gandhi, P; Halker Singh, RB; Lipton, RB; Ma, J; McVige, J; Mechtler, L; Stokes, J; Yu, SY | 1 |
6 review(s) available for pyrroles and atogepant
| Article | Year |
|---|---|
Atogepant: First Approval.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Drug Approval; Drug Interactions; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds; United States; United States Food and Drug Administration | 2022 |
The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.
Topics: Analgesics; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome | 2022 |
Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
Topics: Analgesics; Calcitonin Gene-Related Peptide; Double-Blind Method; Headache; Humans; Migraine Disorders; Multicenter Studies as Topic; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome | 2022 |
Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
Topics: Adult; Analgesics; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Quality of Life; Spiro Compounds | 2022 |
Gepants - a long way to cure: a narrative review.
Topics: Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds | 2022 |
A Brief Review of Gepants.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Pyridines; Pyrroles; Raynaud Disease | 2023 |
9 trial(s) available for pyrroles and atogepant
| Article | Year |
|---|---|
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults.
Topics: Administration, Oral; Adult; Alanine Transaminase; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Humans; Liver; Liver Function Tests; Male; Middle Aged; Migraine Disorders; Piperidines; Placebos; Pyridines; Pyrroles; Spiro Compounds; Young Adult | 2021 |
Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
Topics: Administration, Oral; Aged; Calcitonin Gene-Related Peptide Receptor Antagonists; Female; Half-Life; Humans; Liver Diseases; Male; Middle Aged; Piperidines; Pyridines; Pyrroles; Severity of Illness Index; Spiro Compounds | 2021 |
A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
Topics: Adolescent; Adult; Area Under Curve; Calcitonin Gene-Related Peptide Receptor Antagonists; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Moxifloxacin; Piperidines; Pyridines; Pyrroles; Spiro Compounds; Young Adult | 2021 |
Atogepant for the Preventive Treatment of Migraine.
Topics: Adolescent; Adult; Aged; Calcitonin Gene-Related Peptide Receptor Antagonists; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Migraine Disorders; Nausea; Piperidines; Pyridines; Pyrroles; Spiro Compounds; Young Adult | 2021 |
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Topics: Analgesics; Double-Blind Method; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds; Treatment Outcome | 2022 |
Literature Commentary.
Topics: Aged; Aspirin; Humans; Ophthalmology; Piperidines; Pyridines; Pyrroles; Retrospective Studies; Spiro Compounds; Stroke | 2021 |
Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial.
Topics: Adult; Area Under Curve; Cross-Over Studies; Drug Interactions; Humans; Piperidines; Pyridines; Pyrroles; Spiro Compounds; Sumatriptan | 2022 |
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Analgesics; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds; Treatment Outcome | 2022 |
Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Drug Administration Schedule; Humans; Migraine Disorders; Patient Reported Outcome Measures; Piperidines; Pyridines; Pyrroles; Quality of Life; Spiro Compounds | 2023 |
10 other study(ies) available for pyrroles and atogepant
| Article | Year |
|---|---|
Gepants.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2020 |
Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
Topics: Analgesics; Animals; Botulinum Toxins, Type A; Calcitonin; Humans; Migraine Disorders; Nerve Fibers, Unmyelinated; Piperidines; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Spiro Compounds | 2021 |
Atogepant.
Topics: Analgesics; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |
Atogepant (Qulipta) for migraine prevention.
Topics: Administration, Oral; Calcitonin Gene-Related Peptide Receptor Antagonists; Drug Interactions; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Receptors, Calcitonin Gene-Related Peptide; Signal Transduction; Spiro Compounds; Treatment Outcome | 2021 |
Atogepant: an emerging treatment for migraine.
Topics: Adult; Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |
Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
Topics: Animals; Bayes Theorem; Calcitonin Gene-Related Peptide; Male; Migraine Disorders; Nerve Fibers, Unmyelinated; Nociceptors; Piperidines; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Spiro Compounds | 2022 |
Atogepant (Qulipta®) for migraine prevention.
Topics: Analgesics; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |
Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling.
Topics: Azepines; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Chemical and Drug Induced Liver Injury; Computer Simulation; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |
Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor antagonists.
Topics: Animals; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Charcoal; Constipation; Female; Humans; Intestine, Large; Ligands; Male; Mice; Mice, Transgenic; Piperidines; Pyridines; Pyrroles; Receptor Activity-Modifying Protein 1; Receptors, Calcitonin Gene-Related Peptide; Spiro Compounds | 2022 |
Atogepant for migraine.
Topics: Analgesics; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |